irinotecan
information and resources from the National Cancer Institute
Camptosar
Accel. Approv. (clinical benefit subsequently established) Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
Pharmacia & Upjohn Company Jun 14 1996
Camptosar
Follow up of treatment of metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
Pharmacia & Upjohn Company Oct 22 1998
Camptosar
For first line treatment n combination with 5-FU/leucovorin of metastatic carcinoma of the colon or rectum.
Pharmacia & Upjohn Company Apr 20 2000
|
|
|
|
news articles
Erbitux® Plus Camptosar® Effective in Patients with Colorectal ... Mar 29, 2006
Cancer Consultants (press release), ...published in the British Journal of Cancer, the treatment combination consisting of Erbitux® (cetuximab) and Camptosar® (irinotecan) provides anticancer ...
Chemotherapy Sequence Affects Lung Cancer Response Mar 23, 2006
Cancerpage.com, NEW YORK MAR 22, 2006 (Reuters Health) - Treatment with cisplatin followed by irinotecan appears to achieve better outcome in patients with nonsmall cell lung ...
First Broad Pharmacogenomics Test to Cancer Patients Mar 7, 2006
eMaxHealth.com, ...its laboratory to determine through genetic screening which patients are likely to have a serious adverse reaction to irinotecan hydrochloride (Camptosar®), a ...
Grapefruit and Prescription Drugs: Mix Carefully Mar 30, 2006
PakTribune.com, St. John’s wort is an herb commonly used by people to improve mood, and can interfere with the metabolism of irinotecan, a standard chemotherapy treatment. ...
Pro-Pharmaceuticals Completes Patient Enrollment in Stage 1 of ... Mar 30, 2006
Genetic Engineering News, ...clinical and pre-clinical studies with its lead product candidate, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin ...
90% of Cancer Patients Completely Unaware of New Breakthrough ... Mar 27, 2006
CNW Telbec (Communiqués de presse), ...colon or rectum in combination with the chemotherapy regimens of intravenous 5-fluorouracil/folinic acid or intravenous 5-fluorouracil/folinic acid/irinotecan. ...
FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck ... Mar 1, 2006
Genetic Engineering News, This is the second indicated tumor type for ERBITUX, previously approved by the FDA for use in combination with irinotecan for patients with EGFR-expressing ...
FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck ... Mar 1, 2006
Finanzen.net, This is the second indicated tumor type for ERBITUX, previouslyapproved by the FDA for use in combination with irinotecan forpatients with EGFR-expressing ...
Addition of Erbitux® to Chemotherapy Promising as Initial ... Mar 7, 2006
Cancer Consultants (press release), ...in the Annals of Oncology, the addition of Erbitux® (cetuximab) to the chemotherapy combination consisting of Camptosar® (irinotecan), 5-fluorouracil (5-FU ...
Pro-Pharmaceuticals to Present Abstract & Poster at Mass ... Mar 2, 2006
Genetic Engineering News, ..."The data indicates DAVANAT(R) exhibits broad spectrum enhancement of anti-tumor drugs, including 5-Fluorouracil (5-FU), Irinotecan, and AVASTIN(R) in human ...
ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer Mar 2, 2006
BioWorld Online (subscription), Erbitux first was approved by the FDA for use with irinotecan for patients with EGFR-expressing metastatic colorectal cancer who are refractory to irinotecan ...
FDA Approves Erbitux® For Treatment of Head and Neck Cancer Mar 2, 2006
Cancer Consultants (press release), Erbitux was previously FDA-approved to be used in combination with Camptosar® (irinotecan) for the treatment of colorectal cancer that has stopped responding ...
FDA gives greenlight for new treatment of head and neck cancer Mar 4, 2006
News-Medical.net, Erbitux was previously approved by the FDA to be used in combination with Camptosar (irinotecan) for the treatment of colorectal cancer that no longer responds ...
CORRECTING and REPLACING Sonus Pharmaceuticals Highlights 2005 ... Mar 16, 2006
Genetic Engineering News, ...derivative, provides prolonged exposure to the active drug, leading to better anti-tumor effects, than equivalent doses of irinotecan, a commercially available ...
Insert Therapeutics receives go-ahead for anticancer trials Mar 15, 2006
Pharmaceutical Business Review According to the company, analogues of camptothecin, such as irinotecan and topotecan, realize nearly $1 billion in worldwide sales annually, despite the ...
Pro-Pharmaceuticals' Abstract Accepted for Publication in ASCO ... Mar 17, 2006
International News Service, The Company has been conducting clinical and pre-clinical studies with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and ...
Insert Therapeutics Receives FDA Approval for Nanotechnology-Based ... Mar 14, 2006
AZoNano.com, Analogues of camptothecin, such as irinotecan and topotecan, realize nearly $1 billion in worldwide sales annually, despite the numerous unwanted side effects ...
Predicting Chemotherapy Outcome Mar 22, 2006
Haber Sa?l?k, The microarray analyses were carried out before the patients were treated with combined chemotherapy of folinic acid, 5-fluorouracil and irinotecan. ...
Arrowhead Research Subsidiary, Insert Therapeutics, Receives FDA ... Mar 14, 2006
Finanzen.net, Analogues of camptothecin, such as irinotecan and topotecan,realize nearly $1 billion in worldwide sales annually, despite thenumerous unwanted side effects of ...
NCCN Announces Important Updates to Ovarian Cancer Clinical ... Mar 6, 2006
Genetic Engineering News, ...recurrence modalities for ovarian cancer to include anastrazole (Arimidex, AstraZeneca), bevacizumab (Avastin, Genentech), irinotecan (Camptosar, Pfizer ...
Getting Personal about Drugs Mar 13, 2006
MIT Technology Review, ...oncology will also be important. The FDA recently approved a test to guide the use of irinotecan to treat colon cancer. A new test that ...
Hepatic arterial infusion versus systemic therapy for hepatic ... Mar 1, 2006
News-Medical.net, Because the research began in 1996, before chemotherapy drugs such as irinotecan and oxaliplatin were available, both sets of patients received fluorouracil ...
Heidelberg student donates hair to honor cancer patient Christi ... Mar 6, 2006
Tiffin Advertiser Tribune, Test results in December 2005 showed the irinotecan and temador chemotherapies Christi had been receiving were no longer keeping the cancer stable. ...
U Chicago researchers license pharmacogenomics test for patients ... 21 Dec 2005
EurekAlert (press release), ...researchers have licensed a genetic test that determines which patients are likely to have a serious adverse reaction to irinotecan hydrochloride (Camptosar ...
New genetic tests boost impact of drugs 21 Dec 2005
Pittsburgh Post Gazette, ...test determines whether patients have an genetic variation that increases their risk of a toxic reaction to the colon-cancer drug, called irinotecan, which can ...
Erbitux® Plus Gemzar®/Paraplatin® Promising for Stage IV NSCLC Dec 19, 2005
Cancer Consultants (press release), Erbitux is currently FDA-approved in combination with irinotecan for the treatment of colorectal cancer that has stopped responding to irinotecan-based ...
Genentech Submits Supplemental Biologics License Application for ... Dec 19, 2005
Yahoo! News (press release) ...patients with advanced or metastatic colorectal cancer (CRC) whose disease progressed following previous treatment with 5-FU and irinotecan-based chemotherapy. ...
Hospital cancer drug funding approved Dec 18, 2005
Scoop.co.nz (press release), Studies of combination chemotherapy containing oxaliplatin first-line compared with combination chemotherapy containing irinotecan demonstrated a median five ...
Pro-Pharmaceuticals Issues Corporate Update; Outlines Achievements ... Dec 9, 2005
Genetic Engineering News, ...of DAVANAT(R)/5-FU for third- or fourth-line treatment of patients whose disease progressed despite combination therapies of 5-FU, irinotecan and oxaliplatin. ...
Trick or treatment? Dec 16, 2005
Australian, ..."For example, St John's wort, a popular herbal antidepressant, interferes with the effectiveness of irinotecan, a drug widely used for the treatment of colon ...
Pro-Pharmaceuticals Announces Two International Clinical Sites in ... Dec 13, 2005
Genetic Engineering News, ...clinical trial for second line treatment of patients with metastatic colorectal cancer who failed combination therapies that included irinotecan or oxaliplatin ...
Molecular Advances Driving New Approaches in Colorectal Cancer ... Nov 18, 2005
DG News ...antibodies cetuximab and bevacizumab, the oral pro-drug capecitabine, the platin analog oxaliplatin and the antineoplastic agent irinotecan as agents that are ...
Use of Chemotherapy After Surgery for Colon Cancer Has Risen Dec 6, 2005
Newswise (press release) ...“Future studies are needed to identify whether newer agents such as irinotecan and oxaliplatin may be more effective in patients with high-grade cancers or ...
Use of Chemotherapy after Surgery for Colon Cancer Has Risen Dec 7, 2005
DG News ..."Future studies are needed to identify whether newer agents such as irinotecan and oxaliplatin may be more effective in patients with high-grade cancers or in ...
Rise in Chemotherapy for Colon Cancer Coincides With Improved ... Dec 7, 2005
Medscape (subscription) ..."Our data predate the use of some newer chemotherapeutic agents, such as irinotecan and oxaliplatin, that may further improve outcome.".
Universal Adjuvant Chemotherapy Use Is Elusive for Advanced Colon ... Dec 6, 2005
MedPage Today, ...leucovorin), but the researchers suggested that studies are needed to see if newer regimens - using such drugs as Camptosar (irinotecan) or Eloxatin ...
Genzyme Launches Colorectal Cancer Test to Determine Appropriate ... Dec 6, 2005
Yahoo! News (press release) Assay for colorectal cancer patients in the North American market who are being considered for, or currently taking, the chemotherapy Camptosar® (irinotecan). ...
Combination chemotherapies slow small cell lung cancer and cancer ... Nov 30, 2005
PharmaLive.com (press release), ...by Dr. John D. Hainsworth, SCRI director of clinical research, to evaluate the activity of combination chemotherapy of gemcitabine and irinotecan in patients ...
|
|
